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Summary Allelic losses on the short arm of chromosome 17 occur frequently in colorectal cancers. Despite
the existence of other common molecular events such as loss of the long arms of chromosomes 18 and 5, it has
been demonstrated that the former has the greatest prognostic significance. Of the various genes mapping to
the commonly deleted sequence, the best candidate as a 'target' seems to be the p53 antioncogene. We applied
our methods of detection of the p53 protein in a series of 78 colorectal cancers stored in a tumour bank from
1985 to 1989, for which the median follow-up was 42 months. Nuclear-attached p53 was quantified by flow
cytometry and soluble p53 was assayed by ELISA. Both assays used a monoclonal antibody considered to be
specific for a conformational epitope present only on the mutated protein. Fifty of the 78 tumours (64%) were
found to present significant levels of p53 attached to the nucleus. A further two tumours contained high levels
of p53 only in their soluble fraction. Thus, 52 out of 78 cancers (67%) were considered to be positive for p53.
The p53 content correlated with 17p loss (P<0.002), hyperdiploid DNA content (P<0.001) and tumour site
(P<0.03), but not Dukes' stage (P = 0.15). p53 negative cases had a better overall survival than p53 positive
ones (P<0.03). When the 14 stage D tumours were excluded from the analysis, p53 was no longer
significantly predictive of survival (P<0.07), but remained predictive of recurrence (P<0.02) and metastasis
(P<0.03). Multivariate analysis was not performed because of the small number of cases. Overall, disease-free
and metastasis-free survival were compared to the positivity obtained either with pAb 421 and/or 1801 or pAb
240 since all three were used in the flow cytometric analysis, defining subsets of 421-, 1801 + and 421 -,
1801 -, 240+. The presence of nuclear protein presenting the mutation-specific epitope, recognised by pAb
240, was found to be the most discriminant. It must be noted that univariate survival analysis demonstrated
that more than 80% of patients with p53-negative tumours were alive at 3 years vs less than 50% in the
p53-positive group. A large prospective study should be conducted to define the exact prognostic significance
of the p53 content of colorectal carcinomas.
An increasing body of evidence implicates the cellular anti-
oncogene p53 in the development of human colorectal malig-
nancy. In parallel to the discovery of the recurrent loss of the
short arm of chromosome 17 (17p) by cytogenetic analysis
(Muleris et al., 1985; 1987), allelic losses were described, with
probes specific for the short arm of chromosome 17, as well
as for other chromosome segments (Fearon et al., 1987; Law
et al., 1988; Delattre et al., 1989; Vogelstein et al., 1989;
Fearon et al., 1990). The deletions on 17p were found to
encompass a common region containing the p53 gene (Baker
et al., 1989) and mutations have been described in a number
of cancer specimens (Nigro et al., 1989). More recently, it
was shown that the transfection of a normal p53 gene in
colon carcinoma cells inhibited their growth (Baker et al.,
1990).
Data concerning the expression of the protein have been
obtained by immunochemical methods. Thus, a number of
different groups have reported detection of p53 immunore-
activity in 42-54% of surgical specimens of colorectal
cancer. pAb 421 was the most frequently used anti-p53
monoclonal antibody (Crawford et al., 1984; Van den Berg et
al., 1989; Remvikos et al., 1990), but there has been one
recent report about immunodetection with pAb 1801 (Purdie
et al., 1991) and a small series using pAb 240 (Rodrigues et
al., 1990).
Mutations in the gene have been shown to provoke com-
mon conformational changes recognised by specific mono-
clonal antibodies, defining pAb 246-reactive 'pseudo-wild
type' or 'overtly mutant' protein which reacts with pAb 240
(Gannon et al., 1990). The latter has been applied to breast
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cancer cell lines (Bartek et al., 1990) and human lung car-
cinomas (Iggo et al., 1990), confirming its specificity for the
altered p53 protein.
The aim of the present study was to investigate the influ-
ence of the p53 content of cancer cells on the outcome of the
disease. Two monoclonal antibodies (MAbs) recognising epi-
topes present on the wild-type protein (pAb 421: C-terminal
and 1801: N-terminal) and the mutant-specific pAb 240 were
used. Immunoreactivity was assayed on nuclear suspensions
obtained by dissociation of surgical specimens of colorectal
cancer and on the soluble fractions using a two point ELISA.
Materials and methods
The breast cancer cell line MDA-MB231 was cultured in a
1:1 mixture of DMEM and HAM F12 with 10% foetal calf
serum (FCS) and 2% glutamine. A-431 cells (squamous car-
cinoma of the vulva) and HeLa cells (carcinoma of the
cervix) were cultured in DMEM with 10% FCS. HL-60,
myeloid leukaemia cells were cultured in RPMI 1640 with
20% FCS. In all cases exponentially growing cultures were
harvested as previously described (Hammel et al., 1991) and
stored in liquid nitrogen.
A-431 and MDA-MB231 cells, which have been shown to
contain homozygous p53 mutations (Bartek et al., 1990;
Chen et al., 1990), were used as positive controls, HeLa cells,
in which the p53 protein has been reported to be undetect-
able (Matlashewski et al., 1986), and HL60 cells that do not
contain p53 mRNA consecutive to large deletions in the gene
(Wolf & Rotter, 1985), were used as negative controls.
Seventy-eight specimens of colorectal adenocarcinoma,
operated between November 1985 and December 1989 and
stored in our tumour bank were included in the study. All
tissue fragments from the periphery of the tumours as well as
macroscopically normal mucosa were obtained immediately
after operation and stored at - 80'C for short term conserva-
tion or in liquid nitrogen. These included 2 stage A, 29 stage
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B, 23 stage C and 14 stage D cancers. Nineteen were situated
in the right colon, 35 in the left or sigmoid colon and 24 in
the rectum.
pAb 421 monoclonal antibody (Oncogene Science) and
mouse IgGI and IgG2a immunoglobulins (Southern Bio-
tech.) were purchased as pure solutions. pAb 1801 and 240
anti-p53 monoclonal antibodies in the form of hybridoma
supernatants and the rabbit polyclonal antiserum were gener-
ously provided by Dr D. Lane.
Small tissue fragments were dissociated as previously des-
cribed (Remvikos et al., 1990). Nuclear and soluble fractions
were separated by a 20 s centrifugation at 10,000g. The
nuclear suspensions were stained for FCM analysis, while the
supernatants were used in the ELISA. The tumour nuclei
were filtered on nylon sheets (50ytm mesh), washed once with
PBS and separated into equal fractions before incubation
with the various antibodies.
pAb 421 and isotypic controls were used at 10fig ml-' and
the hybridoma supernatants were diluted to 1/4. All anti-
bodies were diluted in PBS 0.1% BSA. The samples were
incubated in 200pi of the antibody dilution (1 h, room temp-
erature), rinsed in PBS and resuspended in 200 gl of FITC-
conjugated goat anti-mouse immunoglobulins (Southern
Biotech.) diluted to 1/70 and incubated for a further 30 min.
Free fluorescent antiserum was eliminated by centrifugation
and the nuclei were counterstained with propidium iodide
(25 gLgml-') and stored on ice until analysis.
Seventy-three tumours were analysed on a FACSTAR
(Becton-Dickinson), equipped with a doublet discrimination
0
module and five were part of the previously published series
(Remvikos et al., 1990). Settings were log for green fluores-
cence (p53) and linear for red fluorescence (DNA). Graphical
representations and statistics were performed with the Con-
sort 30 software. The fluorescence indices, taking into
account the difference between total and non-specific fluores-
cences measured by FCM, were established for every case.
The threshold value for positivity was 0.50, as previously
described (Remvikos et al., 1990).
Frozen sections from 16 tumours and paraffin sections
from 46 tumours were available for immunohistochemistry.
Endogenous peroxidase activity was inhibited by incubation
with methanol + H202 (0.5%) for 15 min. Sections were incu-
bated with anti-p53 polyclonal antibody CM1 at a dilution of
1:1000 for 1 h and the staining was revealed using the LSAB
kit (DAKO) with diaminobenzidine as the substrate. Haema-
toxylin was used to counterstain nuclei.
A 2-point ELISA was used to detect p53 in the soluble
fractions. The microtitre wells were incubated with anti-p53
polyclonal antibody CM1 at a dilution of 1:1000 for 2 h, and
they were rinsed once with PBS-BSA (0.5%). The wells were
saturated with PBS-BSA (0.5%) for 1 h, and were rinsed
three times with PBS-BSA (0.1%)+ Tween 20 (0.1%). The
soluble fractions from tumours were distributed into the wells
and incubated overnight at 4°C. After three rinses, the wells
were incubated with pAb 240 at a dilution of 1:10 for 2 h at
37°C, and next with peroxidase-conjugated anti-mouse IgGI
at a dilution of 1:3000 for 1 h at 37'C. Background levels
were established in the absence of sample or with samples
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Figure 1 Bivariate DNA/immunofluorescence plots of nuclei stained with isotypic control (a), pAb 1801
240 (d).
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incubated with mouse IgGI (Southern) at 1 gLgml-' instead
of pAb 240. 0-phenylenediamine (ABBOTT) was used as the
coloured substrate of peroxidase. The staining was stabilised
with 4N sulphuric acid and quantified with a TEKAN LP500
at 492 nm.
Differences in survival were tested using the log-rank test
and actuarial survival curves were plotted according to the
Kaplan-Meier method.
Results
An increase in immunofluorescence was observed for some
nuclear suspensions from cancer specimens, incubated in the
presence of anti-p53 monoclonal antibodies. For the diploid
cancer shown in Figure 1, pAb 421 and 1801 produced
similar shifts, while pAb 240 produced a somewhat weaker
one. Six cases showed reproducible 1801 and 240 positivity,
while the fluorescence histogram for 421 was indistinguish-
able from that of the isotypic control (Figure 2). A further
seven cases were shown to react only with pAb 240. As for
the cancer shown in Figure 3, the majority of the nuclei in
the suspensions of six of the seven cases had hyperdiploid
DNA content. The increase in fluorescence for pAb 240 was
observed only for the hyperdiploid component. In some
cases, the staining patterns presented some heterogeneity. For
the case shown in Figure 4, pAb 421 (not shown) or pAb
1801 staining revealed both positive and negative cells, while
the great majority of cells were positive with pAb 240. The
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difference was particularly striking for the cells with S-phase
content. Finally, one cancer showed an increased fluorescence
only for pAb 1801. In this last case, the fluorescence index
for pAb 240 was 0.36, i.e. below the threshold value.
The three MAbs were applied to 73/78 surgical specimens.
Five more cases from our first study (Remvikos et al., 1990)
which were positive for pAb 421 were included in the survival
analysis. Thus 44/73 (60%) of the colorectal adenocarcino-
mas were considered to the positive for pAb 240, compared
to 38/73 (52%) for pAb 1801 and 36/78 (46%) for pAb 421.
There were six cases with 421-, 1801+, 240+ phenotype,
seven with 421-, 1801-, 240+ and one with 421 -, 1801 +,
240-.
The soluble fractions were assayed separately by a 2-point
ELISA, using the polyclonal antiserum as 'capture' antibody
and pAb 240 as the 'revealing' antibody. The sensitivity of
the assay was determined by using serial dilutions of A-431
and MDA-MB231 cells; p53 was measurable down to
200,000 cells/well. Thus, by using approximately 5.106 cells/
well for the soluble fractions it would be possible to measure
down to 1/25th of the p53 expressed in the two cell lines.
Background levels were established using HeLa and HL-60
cells for which the signals obtained did not exceed the con-
trol values (OD = 0.16 ± 0.05). If tumour fragments produc-
ed an insufficient number of cells (less than 3.106 cells) or the
control histograms showed less than 30% non-diploid cells,
ELISA was considered non-informative.
High levels of p53 (OD>0.35), compared to HeLa or
HL-60 cells were obtained for 27/66 tumours (41%). The
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Figure 2 Flow cytometric results for an aneuploid tumour for the left colon, negative for pAb 421 (b), relative to isotypic control
(a), weakly positive for pAb 1801 (c) and distinctly positive for pAb 240 (d).
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Figure 3 DNA histogram (upper panel) for a tumour of the
rectum presenting a major peak of aneuploid tumour cells (right
peak) and a minor peak (left peak) of presumably normal cells.
Regions were set to select the diploid and aneuploid cells in order
to analyse separately their immunofluorescence. Overlay of the
immunofluorescence distributions for the diploid (middle panel)
and aneuploid cells (lower panel), incubated with isotypic control
), pAb 1801 (--) or pAb 240 (. ). A significant shift was
observed for the aneuploid cells and only after incubation with
pAb 240.
remaining 12 cancers included the five pAb 421 + cases from
the previous study and seven cases for which the assay was
considered to be non informative, because of insufficient yield
of tumour nuclei from the fragments. Although FCM and
ELISA results showed a good correlation, a number of
different situations were observed. A high content of nuclear-
attached p53 was demonstrated by FCM for the case shown
in Figure 4, while no p53 was found in the soluble fraction.
On the other hand, the case presented in Figure 5 for which
FCM analysis showed similar levels of nuclear-attached p53
to the previous case, produced one of the strongest signals in
the ELISA.
Only two of the 27 ELISA-positive cases were entirely
negative on FCM. One of them presented positive nuclei on
immunohistochemical analysis (Figure 6) and the other one
only showed faint cytoplasmic staining (not shown).
The p53 content of the 78 cancers was compared to the
other biological parameters (17p loss and DNA content), as
well as pathological stage and tumour site (Table 1). No
significant correlation was found with Dukes' stage (P=
0.15), but a highly significant correlation was obtained with
DNA index > 1.30 (P<0.0001) as well as 17p loss (P<
0.002). p53 content was also significantly different when it
was compared to tumour site (P<0.03), with a considerably
reduced incidence in the proximal colon (42.1% positive
cases) compared to an average of 74.8% in the distal seg-
ments.
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Figure 4 p53/DNA FCM results for a tumour of the rectum
(DNA index 1.15). Equivalent results were obtained with pAb
421 (not shown) and pAb 1801 (b), relative to isotypic control
(a). It must be noted that a more homogenous staining pattern
was obtained with pAb 240 (c), compared to the two other anti
p53 monoclonal antibodies. Extracts from this particular tumour
were repeatedly negative in the ELISA.
The median follow-up for the 78 patients was 42 months.
Actuarial overall survival curves according to a low or high
p53 content are shown in Figure 7 (top panel). A high p53
content was found to be significantly linked to cancer morta-
lity (P<0.03). The analysis was repeated after exclusion of
the 14 stage D patients (not shown); in this case the differ-
ence did not reach statistical significance (P<0.07). The p53
content (for the non-metastatic patients) was found to be
significantly predictive of disease-free (Figure 7: middle
panel, P<0.02) and metastasis-free survival (Figure 7: bot-
tom panel, P<0.03).
Since the p53 content was established by two methods, we
were able to test its prognostic influence in different sub-
groups, according to MAb positivity or FCM vs ELISA. As
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Figure 6 Section of a FCM-negative, ELISA-positive tumour,
presenting distinctly stained nuclei.
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Figure 5 Similar representations to those shown in Figure 4 for
a diploid tumour of the sigmoid, FCM-positive with all three
monoclonal antibodies and high positive in the ELISA.
shown in Table II, the most discriminant factor was found to
be FCM-defined pAb 240 positivity (nuclear attached p53).
Discussion
In our study, FCM analysis was used as a very sensitive
method to investigate the p53 attached to the nuclei of
colorectal carcinomas. Also, the use of monoclonal anti-
bodies specific to the C-terminal (pAb 421) or N-terminal
(pAb 1801) part of the molecule allowed us to demonstrate
the existence of a minor subgroup for which the pAb 421
epitope was absent. More surprisingly, in seven cases there
was evidence of reactivity exclusively with pAb 240. Since six
of these cases had a hyperdiploid DNA content, the separate
analysis of immunofluorescence for the diploid and hyper-
Table I p53 expression in different subgroups
p53 - p53+
Dukes ploidy 17p site
A&B 17 (40.5%) 25 (59.5%) P= 0.15
C&D 9 (25.0%) 27 (75.0%)
< 1.30 19 (59.4%) 13 (40.6%) P<0.0001
> 1.30 7 (15.2%) 39 (84.8%)
Normal 11 (68.7%) 5 (31.3%) P<0.002
Lost 5 (20.0%) 20 (80.0%)
RC 11 (57.9%) 8 (42.1%)
LC 10 (28.6%) 25 (71.4%) P<0.03
REC 5 (20.8%) 19 (79.2%)
diploid components, revealed that the increase in fluorescence
was observed only for the hyperdiploid (presumably malig-
nant) cells. Therefore, it seems improbable that this finding
could be artefactual.
One of the possible criticisms concerning the FCM method
was that the protein would have to remain attached to the
nucleus throughout the processing. In a previous study we
have shown that the use of whole cells released from fresh
surgical specimens provided results similar to those obtained
on nuclear suspensions from frozen fragments of the same
cancers (Hammel et al., 1991). However the effect of the
fixation and permeabilisation procedure prior to application
of the antibodies cannot be accounted for. We therefore
developed a 2-point ELISA in order to quantify p53 in the
soluble fractions of the initial dissociation step. The 'reveal-
ing' antibody in this case was also the mutated p53-specific
pAb 240.
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Figure 7 Actuarial survival curves obtained according to the
Kaplan-Meier method. The Mantel-Cox test was used for the
differences between groups. Upper panel: overall survival (includ-
ing stage D patients). Middle panel: disease-free survival and
lower panel: metastasis-free survival according to p53 content, for
patients with stage A to C2 tumours.
Table II p53 content and survival at 3 years
% Disease % W/O
p53 free metastasis % Alive
Nuclear 421/1801
- 73 80 84
+ 33 59 46
P<0.02 P<0.1 P<0.005
240 - 83 92 88
+ 35 54 45
P<0.005 P<0.02 P<0.007
Nuclear 240 - 82 92 86
and soluble + 38 57 48
P<0.02 P<0.03 P<0.03
One of the advantages of FCM is that by using additional
parameters such as DNA content, the analysis can be selec-
tively performed on cancer cells. ELISA, like all homogenate-
based methods depends on the proportion of malignant cells
in each fragment. For this reason, an aliquot of the initial
suspension, because separation of the nuclear and soluble
fractions, was stained with propidium iodide. Thus, the pro-
portion of cancer cells can be easily determined, provided
that the DNA index is > 1.10 (70% of the present series). In
a previous study comparing FCM and cytogenetic findings,
we discussed this point in relation to the validity of FCM
analysis in general (Remvikos et al., 1988).
By comparing the FCM and ELISA results it was shown
that three pAb 421+, eight pAb 1801+ and 11 pAb 240+
tumours based on the nuclear fractions, had no immunore-
activity p53 in their soluble fractions. Although sensitivity
could have been one explanation, in favour of FCM,
examples were presented with equivalent FCM positivity and
highly divergent ELISA results. Thus it can be hypothesised
that the balance of nuclear attached and soluble p53 in
individual cases, may reflect particular biochemical properties
possibly consecutive to gene mutations. Furthermore, no
nuclear-attached p53 was demonstrated by FCM for two
tumours which produced strong signals on ELISA. Immuno-
histochemical detection of the protein in paraffin embedded
sections revealed positive nuclei for only one of them. The
reasons why despite the nuclear localisation of the protein in
the tissue section, no protein was detected in the nuclear
suspensions prepared repeatedly from the frozen tumour
fragments, is at present unclear. On the other hand, only
weak cytoplasmic staining was observed for the remaining
case. Cytoplasmic staining has been reported for breast
(Bartek et al., 1991), lung cancers (Iggo et al., 1990) and
melanomas (Stretch et al., 1991).
The present study concluded that a high proportion of
human colorectal cancers (67%) express increased levels of
p53 immunoreactive with the mutated protein-specific mono-
clonal antibody pAb 240. However, the association with gene
mutations has yet to be established. A number of colon or
lung cancer cell lines have been described in which p53
protein can behave as mutant, while no evidence of muta-
tions could be obtained (Rodrigues et al., 1990; Lehman et
al., 1991). Thus, a better understanding of the properties of
the p53 variants in colorectal cancers will be achieved after
characterisation of the molecular events at the gene level.
Mutations of the p53 gene have been shown to be related
to the loss of one allele of the short arm of chromosome 17
(Baker et al., 1990). As expected, a similar correlation was
found between 17p loss and increased levels of p53 protein
displaying a mutation-specific epitope. We also observed a
correlation between an increased p53 content and a DNA
index > 1.30. It must be stressed that a DNA index > 1.30
has been previously found to be significantly linked with 17p
loss (Delattre et al., 1989). Thus it seems that the three
parameters, 17p loss, high p53 protein content and hyperdip-
loid DNA content are closely interrelated.
In a series of 78 colorectal tumours, with a median follow-
up of 42 months, we have shown that p53 was predictive of
disease-free and overall survival. FCM-defined pAb 240
positivity was shown to be the most discriminant in terms of
prognosis. This finding could be explained by the fact that
recurrences occur in the high p53 group irrespective of the
presence of the terminal epitopes. Recently, Scott et al. con-
cluded on the absence of prognostic significance of nuclear
p53 (Scott et al., 1991). In their study, pAb 421 was used to
stain p53 on frozen sections. These negative results could be
due to the inability to obtain sufficient information concern-
ing the presence of p53 with this particular MAb.
Because the results concerned only a short series of
patients, we decided not to perform multivariate analysis.
The small number of events in the low p53 group makes the
statistical tests relatively unreliable. Nonetheless, the propor-
tion of patients free of disease in the low p53 group was
strikingly high (>80%), compared to that in the high p53
group (<50%).
Two different studies have concluded on the independent
prognostic significance of 17p loss in colorectal cancers (Kern
et al., 1989; Laurent-Puig et al., 1991). If we consider the
information concerning DNA content, another prognostic
factor according to some reports (Kokal et al. 1986; Jones et
al., 1988), then with the addition of a high p53 protein
content, there are three potentially valuable biological prog-
nostic parameters for colorectal cancers. However, as all
three are closely correlated, only a large prospective study
will be able to define their respective values for clinical
purposes.
Despite the fact that genetic alterations of the p53 gene are
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probably among the most frequently occurring in human
cancers (reviewed in Holstein et al., 1991), this is the first
time that the high content of a protein in the mutant confor-
mation (defined immunologically) was found to influence
patient outcome. The characterisation ofthe mutations might
allow us to determine whether these are simply associated
with the loss of its antioncogenic function or if the increased
expression of the 'mutated' protein is indeed the key event.
In the latter case, it can be hypothesised, at least for colorec-
tal cancers, that p53 mutations can lead a step further from
the recessive antioncogene scheme (Levine et al., 1991), since
some mutations might confer 'oncogenic' properties to the
protein.
References
BAKER, S.J., FEARON, E.R., NIGRO, J.M., HAMILTON, S.T., PRISS-
INGER, A.C., JESSUP,J.M., VAN THUINEN, P., LEDBETTER, D.H.,
BARKER, D.F., NAKAMURA, Y., WHITE, R. & VOGELSTEIN, B.
(1989). Chromosome 17 deletions and p53 gene mutations in
colorectal carcinomas. Science, 244, 217-221.
BAKER, S.J., MARKOWITZ, S., FEARON, E.R, WILSON, J.K. &
VOGELSTEIN, B. (1990). Suppressor of human colorectal car-
cinoma cell growth by wild p53. Science, 249, 912-915.
BAKER, S.J., FREISINGER, A.C., MILBURN JESSUP, J., PARASKEVA,
C., MARKOWITZ, S., WILSON, J.K.V., HAMILTON, S. & VOGEL-
STEIN, B. (1990). p53 gene mutations occur in combination with
17p allelic deletion as late events in colorectal tumourigenesis.
Cancer Res., 50, 7717-7722.
BARTEK, J., IGGO, R., GANNON, J. & LANE, D.P. (1990). Genetic and
immunochemical analysis of mutant p53 in human breast cancer
cell lines. Oncogene, 5, 893-899.
CHEN, P.-L., CHEN, Y., BOOKSTEIN, R. & LEE, W.-H. (1990). Genetic
mechanisms of tumor suppression by the human p53 gene.
Science, 250, 1576-1579.
CRAWFORD, L.V., PIM, D.C. & LAMB, P. (1984). The cellular protein
p53 in human tumors. Mol. Cell. Med., 2, 261-272.
DELATTRE, O., OLSCHWANG, S., LAW, D.J., MELOT, T., REMVIKOS,
Y., SALMON, R.J., SASTRE, X., VALIDIRE, P., FEINBERG, A.P. &
THOMAS, G. (1989). Multiple genetic alterations in distal and
proximal colorectal cancer. Lancet, Hi, 353-356.
FEARON, E.R., HAMILTON, S.R. & VOGELSTEIN, B. (1987). Clonal
analysis of human colorectal tumors. Science, 238, 193-197.
FEARON, E.R. & VOGELSTEIN, B. (1990). A genetic model for colo-
rectal tumorigenesis. Cell, 61, 759-767.
GANNON, J.V., GREAVES, R., IGGO, R. & LANE, D.P. (1990). Acti-
vating mutations in p53 produce a common conformation effect.
EMBO J., 9, 1595-1602.
HAMMEL, P.R., BEUVON, F.X., SALMON, R.J. & REMVIKOS, Y.
(1991). Immunochemical evidence of a mutated p53 protein ex-
pressed in human colorectal adenocarcinoma. Gastroenterol. Clin.
Biol., 15, 529-535.
HOLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. & HARRIS, C.C.
(1991). p53 mutations in human cancers. Science, 253, 49-53.
IGGO, R., GATTER, K., BARTEK, J. & LANE, D. (1990). Increased
expression of mutant forms of p53 oncogene in primary lung
cancer. Lancet, 335, 675-679.
KERN, S.E., FEARON, E.R., TERSMETTE, K.W.F., ENTERLINE, J.P.,
LEPPERT, M., NAKAMURA, Y., WHITE, R., VOGELSTEIN, B. &
HAMILTON, S.R. (1989). Clinical and pathologic associations with
allelic loss in colorectal carcinomas. JAMA, 261, 3099-3103.
KOKAL, W., SHEIBANI, K., TERZ, J. & HARADA, R. (1986). Tumor
DNA content in the prognosis of colorectal carcinoma. J. Am.
Med. Assoc., 255, 3123-3217.
JONES, D.J., MOORE, M. & SCOFIELD, P.F. (1988). Refining the
prognostic significance of DNA ploidy in colorectal cancer; a
prospective flow cytometry study. Int. J. Cancer, 41, 206-210.
LAURENT-PUIG, P., OLSCHWANG, S., DELATTRE, O., REMVIKOS,
Y., ASSELAIN, B., MELOT, T., VALIDIRE, P., MULERIS, M., GIRO-
DET, J., SALMON, R.J. & THOMAS, G. (1992). Survival and soma-
tically acquired alterations in colorectal cancer. Gastroenterology,
(in press).
LAW, D., OLSCHWANG, S., MONPEZAT, J.P., LEFRANCOIS, D.,
JAGELMAN, D., PETRELLI, N.J., THOMAS, G. & FEINBERG, A.
(1988). Concerted nonsynthenic allelic loss in human colorectal
carcinoma. Science, 241, 961-963.
LEHMAN, T.A., BENNET, W.P., METCALF, R.A., WELSH, J.A.,
MODALI, R.V., ULRICH, S., ROMANO, J.W., APELLA, E., TESTA,
J.R., GERWIN, B.J. & HARRIS, C.C. (1991). p53 mutations, ras
mutations and p53-heat shock 70 protein complexes in human
lung carcinoma cell lines. Cancer Res., 51, 4090-4096.
LEVINE, A.J., MOMAND, J. & FINLAY, C.A. (1991). The p53 tumor
suppressor gene. Nature, 351, 453-456.
MATLASHEWSKI, G., BANKS, L., PIM, D. & CRAWFORD, L. (1986).
Analysis of human p53 protein in normal and transformed cells.
Eur. J. Biochem., 154, 665-672.
MULERIS, M., SALMON, R.J., ZAFRANI, B., GIRODET, J. & DUTRIL-
LAUX, B. (1985). Consistent deficiencies of chromosome 18 and
of the short arm of chromosome 17 in eleven cases of human
large bowel cancer: a possible recessive determinism. Ann. Genet.,
28, 206-213.
MULERIS, M., SALMON, R.J., DUTRILLAUX, A.M., VIELH, P., ZAF-
RANI, B., GIRODET, J. & DUTRILLAUX, B. (1987). Characteristic
chromosomal imbalances in 18-near-diploid colorectal tumors.
Cancer Genet. Cytogenet., 29, 289-301.
NIGRO, J.M., BAKER, S.J., PREISINGER, A.C., JESSUP, J.M., HOSTET-
TER, R., CLEARY, K., BIGNER, S.H., DAVIDSON, N., BAYLIN, S.,
DEVILEE, P., GLOVER, T., COLLINS, F.S., WESTON, A., MODALI,
R., HARRIS, C.C. & VOGELSTEIN, B. (1989). Mutations in the p53
gene occur in diverse tumour type. Nature, 342, 705-708.
PURDIE, C.A., O'GRADY, J., PIRIS, J., WYLLIE, A.H. & BIRD, C.C.
(1991). p53 expression in colorectal tumors. Am. J. Pathol., 138,
807-813.
REMVIKOS, Y., MULERIS, M., VIEHL, P., SALMON, R.J. & DUTRIL-
LAUX, B. (1988). DNA content and genetic evolution of human
colorectal adenocarcinoma. A study by flow cytometry and cyto-
genetic analysis. Int. J. Cancer, 42, 539-543.
REMVIKOS, Y., LAURENT-PUIG, P., SALMON, R.J., FRELAT, G.,
DUTRILLAUX, B. & THOMAS, G. (1990). Simultaneous monitor-
ing of p53 protein and DNA content of colorectal adenocar-
cinomas by flow cytometry. Int. J. Cancer, 45, 450-456.
RODRIGUES, N.R., ROWAN, A., SMITH, M.E.F., KERR, I.B., BOD-
MER, W.F., GANNON, J.V. & LANE, D.P. (1990). p53 mutations in
colorectal cancer. Proc. Natl Acad. Sci. USA, 87, 7555-7559.
SCOTT, N.P., SAGAR, P., STEWART, J., BLAIR, G.E., DIXON, M.F. &
QUIRKE, P. (1991). p53 in colorectal cancer: clinicopathological
correlations and prognostic significance. Br. J. Cancer, 63,
317-319.
STRECH, J.R., GATTER, K.C., RALFKIAER, E., LANE, D.P. & HAR-
RIS, A.L. (1991). Expression of mutant p53 in melanoma. Cancer
Res., 51, 5976-5979.
VAN DEN BERG, F.M., TIGGES, A.J., SCHIPPER, M.E.I., DEN HARTOG-
JAGER, F.C.A., KROE, W.G.M. & WALBOMERS, J.M.M. (1989).
Expression of the nuclear oncogene p53 in colon tumours. J.
Pathol., 157, 193-199.
VOGELSTEIN, B., FEARON, E.R., KERN, S.E., HAMILTON, S.R., PREI-
SINGER, A.C., NAKAMURA, Y. & WHITE, R. (1989). Allelotype of
colorectal carcinomas. Science, 244, 207-211.
WOLF, D. & ROTTER, V. (1985). Major deletions in the gene encod-
ing the p53 tumor antigen cause lack of p53 expression in HL-60
cells. Proc. Natl Acad. Sci. USA, 82, 790-794.